Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ciprofloxacin hydrochloride
Drug ID BADD_D00472
Description Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
Indications and Usage For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
Marketing Status Prescription; Discontinued
ATC Code J01MA02; S01AE03; S02AA15; S03AA07
DrugBank ID DB00537
KEGG ID D02216
MeSH ID D002939
PubChem ID 62999
TTD Drug ID D0O1WX
NDC Product Code 50090-3791; 17478-714; 43063-923; 68999-309; 70518-1278; 70518-1234; 50090-5628; 63187-150; 59390-217; 68071-2382; 62135-308; 52286-0005; 0078-0841; 50090-5671; 61442-222; 68788-8136; 53069-0180; 48589-0001; 51943-112; 45865-721; 12527-8513; 50419-754; 16714-653; 62704-0030; 53002-1320; 65862-076; 71901-602; 72789-006; 51672-4085; 50090-0881; 63629-8344; 50090-3130; 61314-656; 62991-2518; 38779-0534; 76420-045; 0065-0656; 63629-1010; 71610-159; 63629-7648; 50090-5373; 50090-5371; 70934-093; 68071-4139; 58032-0006; 72189-111; 52286-0015; 71335-2046; 65862-077; 62135-310; 16714-652; 66021-0003; 71335-1024; 49452-2080; 0404-7187; 55700-884; 50090-4600; 63739-559; 50090-2146; 61442-223; 55154-2081; 65862-078; 45865-877; 71335-0836; 16714-651; 62135-309; 50090-1754; 53104-7518; 68084-070; 68071-4492; 51672-4087; 71335-1347; 50090-3852; 63629-7717; 71205-997; 68071-2440; 71610-109; 51927-0236; 51672-4086; 68071-4576; 68071-3351; 71205-536; 71205-636; 68071-2290; 67296-1696; 50419-758; 12527-8512; 55154-8148; 68071-4627; 63739-700; 55111-010; 71205-649; 72789-065; 61442-224; 55154-2086; 63187-985; 65862-379; 51407-165; 53002-9320
Synonyms Ciprofloxacin | Ciprofloxacin Hydrochloride Anhydrous | Anhydrous, Ciprofloxacin Hydrochloride | Hydrochloride Anhydrous, Ciprofloxacin | Cipro | Ciprofloxacin Hydrochloride | Hydrochloride, Ciprofloxacin | Ciprofloxacin Monohydrochloride Monohydrate | Monohydrate, Ciprofloxacin Monohydrochloride | Monohydrochloride Monohydrate, Ciprofloxacin | Bay-09867 | Bay 09867 | Bay09867 | Ciprinol
Chemical Information
Molecular Formula C17H19ClFN3O3
CAS Registry Number 86483-48-9
SMILES C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute hepatic failureAlanine aminotransferase 1P24298Not AvailableNot Available
Acute hepatic failureAspartate aminotransferase, mitochondrialP00505Not AvailableNot Available
DeathDNA gyrase subunit AP48369Not AvailableNot Available
HaematotoxicityAlanine aminotransferase 1P24298Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Prothrombin time shortened13.01.02.013--Not Available
Pruritus23.03.12.001--
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Restlessness17.02.05.021; 19.11.02.002--
Rhinitis22.07.03.006; 11.01.13.004--
Seizure17.12.03.001--
Serum sickness-like reaction10.01.03.005; 08.01.03.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin irritation23.03.04.009--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 10.01.03.020; 11.07.01.005--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.007--Not Available
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Tendonitis15.07.01.003; 12.01.07.007--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Torsade de pointes02.03.04.005--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vasculitis24.05.02.001; 10.02.02.006--
Ventricular extrasystoles02.03.04.007--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages